FDA: Bevacizumab Should No Longer Be Indicated for Breast Cancer

The drug also recently failed to improve pathological complete response in a large, European trial among women with primary HER2-negative breast cancer who were given a neoadjuvant regimen that combined bevacizumab with epirubicin, cyclophosphamide, and docetaxel. The results were reported at the San Antonio Breast Cancer Symposium.